Managing the symptoms of Behçet’s disease

Bibliography

• BEKET H: Uber rezidivierende Aphthose, durch em Virus verursachte Geschwure am Mund, am Auge und an den Genitalien. Dermatel Wechenschr. (1937) 105:1152–1157.
   Google Scholar
• EVEREKLIOGLU C, ER H: Increased corneal thickness in active Behget's disease. Ear. Ophthalmel. (2002) 12:24–29.
   PubMed Web of Science ®Google Scholar
• EVEREKLIOGLU C, YOREKLI M, ER H et al.: Increased plasma adrenomedullin levels in patients with Behget's disease. Dermatology (2000) 201:312–315.
   PubMedGoogle Scholar
• EVEREKLIOGLU C, INALOZ HS, KIRTAK N et al.: Serum leptin concentration is increased in patients with Behget's syndrome and is correlated withdisease activity. Br. J. Dermatel (2002) 147:331–336.
   PubMedGoogle Scholar
• EVEREKLIOGLU C, TORKOZ Y, ER H,INALOZ HS, OZBEK E, cEKMEN M: Increased nitric oxide production in patients with Behget's disease: is it a new activity marker?' Am. Acad. Dermatel. (2002) 46:50–54.
   PubMed Web of Science ®Google Scholar
• EVEREKLIOGLU C, cEKMEN M, OZKIRIS A, KARABAS L, cALIS M: The pathophysiological significance of red blood cell nitric oxide concentrations in
   Google Scholar
• ••inflammatory Behget's disease. Mediators Inflamm. (2003) 12:255–256.
   Google Scholar
• EVEREKLIOGLU C, ER H, TORKOZ Y, CEKMEN M: Serum levels of TNF-a, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behget's disease. Mediators Inflamm. (2002) 11:87–93.
   PubMed Web of Science ®Google Scholar
• TORKOZ Y, EVEREKLIOGLU C, MEHMET N, CEKMEN M, ER H: Plasma malondialdehyde levels in Behget's disease with or without ocular involvement. Adv. Reprod. (2000) 4:31–36.
   Google Scholar
• ERKILIC K, EVEREKLIOGLU C, CEKMEN M, OZKIRIS A, DUYGULU F, DOGAN H: Adenosine deaminase enzyme activity is increased and negatively correlates with catalase, superoxide dismutase and glutathione peroxidase in patients with Behget's disease: original contributions/clinical and laboratory investigations. Mediators Inflamm. (2003) 12:107–116.
   PubMedGoogle Scholar
• YAZICI H, CHAMBERLAIN MA, SCHREUDER I, D'AMARO J, MOFTOOGLU M: HLA antigens in Behget's disease: a reappraisal by a comparative study of Turkish and British patients. Ann. Rheum. Dis. (1980) 39:344–348.
   PubMed Web of Science ®Google Scholar
• OHNO S, OHGUCHI M, HIROSE S, MATSUDA H, WAKISAKA A, AIZAWA M: Close association of HLA-Bw51 with Behget's disease. Arch. Ophthalmol (1982) 100:1455–1458.
   PubMed Web of Science ®Google Scholar
• MIZUKI N, INOKO H, OHNO S: Pathogenic gene responsible for the predisposition to Behget's disease. Int. Rev Immunol (1997) 14:33–48.
   PubMedGoogle Scholar
• DIRESKENELI H: Behget's disease: infectious aetiology, new autoantigens, and HLA-B51. Ann. Rheum. Dis. (2001) 60:996–1002.
   PubMed Web of Science ®Google Scholar
• DIRESKENELI H, KESER G, D'CRUZ Det al.: Anti-endothelial cell antibodies, endothelial proliferation and von Willebrand factor antigen in Behget's disease. Clin. Rheumatol (1995) 14:55–61.
   Google Scholar
• WECHSLER B, DU LT, KIEFFER E: Cardiovascular manifestations of Behget's disease. Ann. Med. Intern. (1999) 150:542–554.
   PubMedGoogle Scholar
• HIROHATA S, OKA H, MIZUSHIMA Y: Streptococcal-related antigens stimulate production of IL-6 and interferon-gamma by T cells from patients with Behget'sdisease. Cell. Immunol (1992) 140:410–419.
   PubMedGoogle Scholar
• SOHN S, LEE ES, BANG D LEE S: Behget's disease-like symptoms induced by the herpes simplex virus in ICR mice. Eur. Dermatol (1998) 8:21–23.
   PubMed Web of Science ®Google Scholar
• ERGON T, INCE 0,EKSIOGLU-DEMIRALP E et al: HSP 60 expression in mucocutaneous lesions of Behget's disease. Am. Acad. Dermatol (2001) 45:904–909.
   PubMedGoogle Scholar
• LEHNER T: The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behget's disease. Int. Rev Immunol (1997) 14:21–32.
   PubMedGoogle Scholar
• GHATE JV, JORIZZO JL: Behget's disease and complex aphthosis. I Am. Acad. Dermatol (1999) 40:1–18.
   PubMed Web of Science ®Google Scholar
• ONDER M, GORER MA: Behget's disease: an enigmatic vasculitis. Clin. Berm. (1999) 17:571–576.
   Google Scholar
• O'DUFFY JD: Vasculitis in Behget's disease. Rheum. Dis. Clin. North. Am. (1990) 16:423–431.
   Google Scholar
• POULTER LW, LEHNER T: Immunohistology of oral lesions from patients with recurrent oral ulcers and Behget's syndrome. Clin. Exp. Immunol (1989) 78:189–195.
   PubMed Web of Science ®Google Scholar
• EHRLICH GE: Vasculitis in Behget's disease. Int. Rev Immunol (1997) 14:81–88.
   PubMedGoogle Scholar
• ONDER M, GORER MA: The multiple faces of Behget's disease and its aetiological factors. Eur. Acad. Dermatol Venereol (2000) 15:126–136.
   Google Scholar
• DILSEN N: History and development of Behget's disease. Rev. Rheum. Engl. Ed. (1996) 63:512–519.
   PubMedGoogle Scholar
• KAKLAMANI VG, VAIOPOULOS G, KAKLAMANIS PG: Behget's disease. Semin. Arthritis Rheum. (1998) 27:197–217.
   PubMed Web of Science ®Google Scholar
• LEE LA: Behget's disease. Semin. Cutan. Med. Surg. (2001) 20:53–57.
   PubMed Web of Science ®Google Scholar
• NISHIYAMA M, NAKAE K,KURIYAMA T, HASHIMOTO M, HSU ZN: A study among related pairs of Japanese patients with Behget's disease: group comparisons by interval of disease onset. Rheumatol (2002) 29:743–747.
   Google Scholar
• NISHIYAMA M, NAKAE K,UMEHARA T: A study of familial occurrence of Behget's disease with and without ocular lesions. fpn. I Ophthalmol (2001) 45:313–316.
   Google Scholar
• YAZICI H, TUZUNY, PAZARLI H et al.: Influence of age of onset and patient's sex onthe prevalence and severity of manifestations of Behget's syndrome.Ann. Rheum. Dis. (1984) 43:783–789.
   PubMedGoogle Scholar
• ANDO K, FUJINO Y, HIJIKATA K, IZAWA Y, MASUDA K: Epidemiological features and visual prognosis of Behget's disease. fpn..1. Ophthalmol (1999) 43:312–317.
   Google Scholar
• TURSEN U, GORLER A, BOYVAT A: Evaluation of clinical findings according to sex in 2313 Turkish patients with Behget's disease. Int. Dermatol (2003) 42:346–351.
   PubMed Web of Science ®Google Scholar
• ZOUBOULIS CC: Epidemiology of Adamantiades-Behget's disease.Ann. Med. Interne. (1999) 150:488–498.
   PubMedGoogle Scholar
• SAKANE T, TAKENO M, SUZUKI N, INABA G: Behget's disease. N Engl. I Med. (1999) 341:1284–1291.
   PubMed Web of Science ®Google Scholar
• MASON RM, BARNES CG: Behget's syndrome with arthritis. Ann. Rheum. Dis. (1969) 28:95–103.
   PubMed Web of Science ®Google Scholar
• BEKET'S DISEASE RESEARCH COMMITTEE OF JAPAN: Behget's disease: a guide to diagnosis of Behget's disease. fpn..1. Ophthalmol (1974) 18:291–294.
   Google Scholar
• O'DUFFY JD, GOLDSTEIN NP: Neurologic involvement in seven patients with Behget's disease. Am. I Med. (1976) 61:170–178.
   Google Scholar
• MIZUSHIMA Y: Recent research into Behget's disease in Japan. Int. .1. Tissue React. (1988) 10:59–65.
   Google Scholar
• INTERNATIONAL STUDY GROUP FOR BEKET'S DISEASE: Criteria for diagnosis of Behget's disease. Lancet (1990) 335:1078–1080.
   PubMedGoogle Scholar
• ••This diagnostic criteria has specificity andsensitivity for the diagnosis of BD to perform international comparative studies.
   Google Scholar
• SCHIRMER M, CALAMIA KT, O'DUFFY JD: Is there a place for large vessel disease in the diagnostic criteria of Behget's disease?' Rheumatol (1999) 26:2511–2512.
   Google Scholar
• YAZICI H: Behget's syndrome: where dowe stand? Am.' Med. (2002) 112:75–76.
   Google Scholar
• SAKANE T, TAKENO M: Novel approaches to Behget's disease. Expert Opin. Investig. Drugs. (2000) 9:1993–2005.
   PubMed Web of Science ®Google Scholar
• SHEK LP, LIM DL: Thalidomide in Behget's disease. Biomed. Pharmacother. (2002) 56:31–35.
   PubMed Web of Science ®Google Scholar
• SCHREINER DT, JORIZZO JL: Behcet's disease and complex aphthosis. Dermatol Clin. (1987) 5:769–778.
   PubMed Web of Science ®Google Scholar
• GORLER A, BOYVAT A, TURSEN U: Clinical manifestations of Behcet's disease: an analysis of 2147 patients. Yonsei Med. J. (1997) 38:423–427.
   PubMedGoogle Scholar
• ALPSOY E, UZUN S, AKMAN A, ACAR MA, MEMISOGLU HR, BASARAN E: Histologic and immunofluorescence findings of non-follicular papulopustular lesions in patients with Behcet's disease. J. Ear: Acad. Dermatol Venereol (2003) 17:521–524.
   PubMed Web of Science ®Google Scholar
• INALOZ HS, EVEREKLIOGLU C, ONAL B, KIRTAK N, ERALP A, INALOZ SS: The significance of immunohistochemistry in the skin pathergy reaction of patients with Behcet's syndrome. Eur. Acad. Dermatol Venereol (2003) (In Press).
   Google Scholar
• YAZICI H, CHAMBERLAIN MA, TOZON Y, YURDAKUL S, MOFTOOGLU A: A comparative study of the pathergy reaction among Turkish and British patients with Behcet's disease. Ann. Rheum. Dis. (1984) 43:74–75.
   PubMed Web of Science ®Google Scholar
• DAVIES PG, FORDHAM JN, KIRWAN JR, BARNES CG, DINNING WJ: The pathergy test and Behcet's syndrome in Britain. Ann. Rheum. Dis. (1984) 43:70–73.
   PubMed Web of Science ®Google Scholar
• FREIDMAN-BIRNBAUM R,BERGMAN R, AIZEN E: Sensitivity and specificity of pathergy results in Israeli patients with Behcet's disease. Cutts (1990) 45:261–264.
   PubMedGoogle Scholar
• KURAL-SEYAHI E, FRESKO I, SEYAHI N et al.: The long-term mortality and morbidity of Behget syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center.Medicine (2003) 82:60–76.
   PubMed Web of Science ®Google Scholar
• NUSSENBLATT RB: Uveitis in Behcet's disease. Int. Rev Immunol (1997) 14:67–79.
   PubMedGoogle Scholar
• ER H, EVEREKLIOGLU C,CUMURCU T et al.: Serum homocysteine level is increased and correlated with endothelin-1 and nitric oxide in Behcet's disease. Br: J. Ophthalmol (2002) 86:653–657.
   Google Scholar
• •This study demonstrated for the first time that elevated homocysteine may be a risk factor for retinal vascular occlusive disease.
   Google Scholar
• GEORGE RK, CHAN CC,WHITCUP SM, NUSSENBLATT RB: Ocular immunopathology of Behcet'sdisease. Surv. Ophthalmol (1997) 42:157–162.
   PubMed Web of Science ®Google Scholar
• PALMER HE, ZAMAN AG, EDELSTEN CE, STANFORD MR, GRAHAM EM: Systemic morbidity in patients with isolated idiopathic retinal vasculitis. Lancet (1995) 346:505–506.
   PubMedGoogle Scholar
• EL BELHADJI M, HAMDANI M, LAOUISSI N, ZAGHLOUL K, AMRAOUI A, BENAMOUR S: Ophthalmological involvement in Behget disease. Apropos of 520 cases. J. Fr. Ophtalmol (1997) 20:592–598.
   PubMedGoogle Scholar
• PAMIR MN, KANSU T, ERBENGI A, ZILELI T: Papilledema in Behcet's syndrome. Arch. Neurol (1981) 38:643–645.
   PubMedGoogle Scholar
• SAKAMOTO M, AKAZAWA K, NISHIOKA Y, SANUI H, INOMATA H, NOSE Y: Prognostic factors of vision in patients with Behcet's disease. Ophthalmology (1995) 102:317–321.
   PubMed Web of Science ®Google Scholar
• DILSEN N, KONICE M, ARAL 0, ()CAL L, INANC M, MR A: Risk factors for vital organ involvement in Behcet's disease. In: Behret's disease. International Congress series 1037. Wechsler B, Godeau P, (Eds), Excerpta Medica, Amsterdam, (1993):165–169.
   Google Scholar
• NAKAE K, MASAKI F, HASHIMOTO T, INABA G, MOSHIZUKI M, SAKANE T: Recent epidemiological features of Behcet's disease in Japan. In: Behret's disease. International Congress series 1037 Wechsler B, Godeau P, (Eds), Excerpa Medical, Amsterdam, The Netherlands (1993):145–151.
   Google Scholar
• YURDAKUL S, YAZICI H, TOZON Y et al.: The arthritis of Behcet's disease: a prospective study. Ann. Rheum. Dis. (1983) 42:505–515.
   PubMed Web of Science ®Google Scholar
• KIM HA, CHOI KW, SONG YW: Arthropathy in Behcet's disease. Scand. Rheumatol (1997) 26:125–129.
   PubMed Web of Science ®Google Scholar
• PICKERING MC, HASKARD DO: Behcet's syndrome. JR Coll. Physicans Lond. (2000) 34:169–177.
   PubMedGoogle Scholar
• PARK JH: Clinical analysis of Behget disease: arthritic manifestations in Behget disease may present as seronegative rheumatoid arthritis or palindromic rheumatism. Korean J. Intern. Med. (1999) 14:66–72.
   PubMedGoogle Scholar
• SERDAROGLU P: Behcet's disease and the nervous system. Neurol (1998) 245:197–205.
   Google Scholar
• TOHME A, HADDAD F, GHAYAD E: Neurologic manifestations in Behcet's disease. 16 cases in a cohort of 110 patients. Ann. Med. Interne. (1997) 148:118–124.
   Google Scholar
• KIDD D, STEUER A, DENMAN AM, RUDGE P: Neurological complications in Behcet's syndrome. Brain (1999) 122:2183–2194.
   PubMed Web of Science ®Google Scholar
• AKMAN-DEMIR G, SERDAROGLU P, TASCI B: Clinical patterns of neurological involvement in Behcet's disease: evaluation of 200 patients. The Neuro-Behget Study Group. Brain (1999) 122:2171–2182.
   Google Scholar
• BRAMA I, FAINARU M: Inner ear involvement in Behcet's disease.Arch. Otolaryngol (1980) 106:215–217.
   PubMedGoogle Scholar
• BELKAHIA A, BEN AYED H,BEN H'MIDA M, HAMZA M: Auditory and vestibular lesions in Behcet's disease. Ann. Otolaryngol Chir. Cervicofac. (1982) 99:469–476.
   PubMedGoogle Scholar
• GEMIGNANI G, BERRETTINI S, BRUSCHINI P et al.: Hearing and vestibular disturbances in Behcet's syndrome. Ann. OW Rhino]. Laryngol (1991) 100:459–463.
   PubMed Web of Science ®Google Scholar
• EVEREKLIOGLU C, COKKESER Y, DOGANAY S, ER H, KIZILAY A: Audio-vestibular evaluation in patients with Behcet's syndrome. J Laryngol Otol (2001) 115:704–708.
   PubMedGoogle Scholar
• KARLIDAG R, ONAL S,EVEREKLIOGLU C, SIPAHI B, ER H, YOLOGLU S: Stressful life events, anxiety, depression and coping mechanisms in patients with Behcet's disease. J Ear: Acad. Dermatol Venereol (2003) 17:670–675.
   PubMed Web of Science ®Google Scholar
• OKTEM-TANOR 0, BAYKAN-KURT B, GURVIT IH, AKMAN-DEMIR G, SERDAROGLU P: Neuropsychological follow-up of 12 patients with neuro-Behget disease. J. Neurol (1999) 246:113–119.
   PubMedGoogle Scholar
• KOC Y, GOLLO I, AKPEK G et al: Vascular involvement in Behcet's disease. J Rheum. (1992) 19:402–410.
   PubMed Web of Science ®Google Scholar
• LAKHANPAL S, TANI K, LIE JT, KATOH K, ISHIGATSUBO Y, OHOKUBO T: Pathologic features of Behget's syndrome: a review of Japanese autopsy registry data. Hum. Pathol (1985) 16:790–795.
   PubMed Web of Science ®Google Scholar
• BAYRAKTAR Y, OZASLAN E, VAN THIEL DH: Gastrointestinal manifestations of Behcet's disease. J. Clin. Castroenterol (2000) 30:144–154.
   PubMed Web of Science ®Google Scholar
• CEKMEN M, EVEREKLIOGLU C, ER H et al.: Vascular endothelial growth factorlevels are increased and associated with disease activity in patients with Behget's syndrome. Int. Dermatol (2003) 42:870–875.
   PubMed Web of Science ®Google Scholar
• HARPER CM JR, O'NEILL BP, O'DUFFY JD, FORBES GS: Intracranial hypertension in Behget's disease: demonstration of sinus occlusion with use of digital subtraction angiography. Mayo Gin. Proc. (1985) 60:419–422.
   PubMedGoogle Scholar
• BOWLES CA, NELSON AM, HAMMILL SC, O'DUFFY JD: Cardiac involvement in Behget's disease. Arthritic Rheum. (1985) 28:345–348.
   PubMedGoogle Scholar
• MOGULKOC N, BURGESS MI, BISHOP PW: Intracardiac thrombus in Behget's disease: a systematic review. Chest (2000) 118:479–487.
   PubMedGoogle Scholar
• MORELLI S, PERRONE C,FERRANTE L et al: Cardiac involvementin Behget's disease. Cardiology (1997) 88:513–517.
   PubMed Web of Science ®Google Scholar
• ERKAN F, KIYAN E, TUNACI A: Pulmonary complications of Behget's disease. Gin. Chest. Med. (2002) 23:493–503.
   PubMedGoogle Scholar
• SLAVIN RE, DE GROOT WJ: Pathology of the lung in Behget's disease: case report and review of the literature. Am. Surg. Pathol (1981) 5:779–788.
   Google Scholar
• TUNACI A, BERKMEN YM, GOKMEN E: Thoracic involvement in Behget's disease: pathologic, clinical, and imaging features. Am. Roentgenol (1995) 164:51–56.
   PubMed Web of Science ®Google Scholar
• PAZ I, OKON E, CHAJEK-SHAUL T: Pulmonary manifestations in Behget's syndrome. Chest (1989) 95:585–589.
   PubMedGoogle Scholar
• ERKAN F, GOL A, TASALI E: Pulmonarymanifestations of Behget's disease. Thorax2001 (2001) 56:572–578.
   PubMed Web of Science ®Google Scholar
• GONEN H, EVEREKLIOGLU C, KOSAR F, ER H, KIZKIN 0: Thoracic involvement in Behget's disease and its correlation with multiple parameters. Lung (2000) 178:161–170.
   PubMedGoogle Scholar
• KASAHARA Y, TANAKA S,NISHINO M, UMEMURA H, SHIRAHA S, KUYUMATA T: Intestinal involvement in Behget's disease: review of 136 surgical cases in the Japanese literature. Dis. Colon Rectum (1981) 24:103–106.
   PubMed Web of Science ®Google Scholar
• YASHIRO K, NAGASAKO K, HASEGAWA K, MARYYAMA M, SUZUKI S, OBATA B: Esophageal lesions in intestinal Behget's disease. Endoscopy (1986) 18:57–60.
   PubMed Web of Science ®Google Scholar
• KORMAN U, CANTASDEMIR M, KURUGOGLU S et al.: Enteroclysis findings of intestinal Behget disease: a comparative study with Crohn disease. Abdom. Imaging. (2003) 28:308–312.
   PubMedGoogle Scholar
• AKPOLAT T, AKKOYUNLU M, AKPOLAT I, DILEK M, ODABAS AR, ()ZEN S: Renal Behget's disease: a cumulative analysis. Semin. Arthritic Rheum. (2002) 31:317–337.
   PubMed Web of Science ®Google Scholar
• YVER L, BLANCHIER D, AOURAGH F et al.: Renal involvement in Behget's disease: case report and review of the literature. Nephron (1996) 73:689–691.
   PubMed Web of Science ®Google Scholar
• EL RAMAHI KM, AL DALAAN A, AL SHAIKH A, AL MESHARI K, AKHTAR M: Renal involvement in Behget's disease: review of 9 cases.Rheumatol (1998) 25:2254–2260.
   Google Scholar
• EVEREKLIOGLU C, OZBEK E, ER H,CEKMEN M, YOREKLI M: Urinary adrenomedullin levels are increased and correlated with plasma concentrations in patients with Behget's syndrome. Int. Um]. (2002) 9:296–303.
   Google Scholar
• EVEREKLIOGLU C, OZBEK E, CEKMEN M et al: Urinary nitric oxide levels are increased and correlated with plasma concentrations in patients with Behget's disease: is it a new urinary activity marker? Nephrology (2003) 8:246–253.
   Google Scholar
• MALIK GH, SIRWAL IA, PANDIT KA: Behget's syndrome associated with minimal change glomerulonephritis and renal vein thrombosis. Nephron (1989) 52:87–89.
   PubMedGoogle Scholar
• HEMMEN T, PEREZ-CANTO A, DISTLER A, OFFERMANN G,BRAUN J: IgA nephropathy in a patient with Behget's syndrome: case report and review of literature. Br.j Rheumatol (1997) 36:696–699.
   PubMedGoogle Scholar
• AKPOLAT T, DIRI B, OGUZ Y, YILMAZ E, YAVUZ M, DILEK M: Behget's disease and renal failure. Nephrol Dial. Transplant. (2003) 18:888–891.
   PubMed Web of Science ®Google Scholar
• KAKLAMANI VG, VAIOPOULOS G, MARKOMICHELAKIS N, KAKLAMANIS P: Recurrent epididymo-orchitis in patients with Behget's disease.Viol (2000) 163:487–489.
   Google Scholar
• CETINEL B, AKPINAR H, TOFEK I, UYGUN N, SOLAK V, YAZICI H: Bladder involvement in Behget's syndrome. Viol (1999) 161:52–56.
   Google Scholar
• GOKER B, GOKER H: Current therapy for Behget's disease. Am. The]: (2002) 9:465–470.
   PubMedGoogle Scholar
• EDRES MA, SCULLY C, GELBIER M: Use of proprietary agents to relieve recurrent aphthous stomatitis. Br. Dent. (1997) 182:144–146.
   PubMed Web of Science ®Google Scholar
• YURDAKUL S, MAT C, TOZON Y et al: A double-blind trial of colchicine in Behget's syndrome. Arthritic Rheum. (2001) 44:2686–2692.
   PubMed Web of Science ®Google Scholar
• ••This 2-year, placebo-controlled studyshowed the effectiveness of colchicine in BD patients with active mucocutaneous disease without eye or major organ involvement.
   Google Scholar
• SHARQUIE KE, NAJIM RA, ABU-RAGHIF AR: Dapsone in Behget's disease: a double-blind, placebo-controlled, cross-over study.' Dermatol (2002) 29:267–279.
   Google Scholar
• •This 12-month placebo-controlled trial showed the effectiveness of dapsone in BD patients with mucocutaneous disease.
   Google Scholar
• YAZICI H, PAZARLI H, BARNES CG et al.: A controlled trial of azathioprine in Behget's syndrome. N Engl. I Med. (1990) 322:281–285.
   PubMed Web of Science ®Google Scholar
• YAZICI H, BARNES CG: Practical treatment recommendations for pharmacotherapy of Behget's syndrome. Drugs (1991) 42:796–804.
   PubMedGoogle Scholar
• MIZUSHIMA Y: Behget's disease. Carr: Opin. Rheumatol (1991) 3:32–35.
   PubMedGoogle Scholar
• MASUDA K, NAKAJIMA A,URAYAMA A, NAKAE K, KOGURE M, INABA G: Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behget's Disease. Lancet (1989) 1:1093–1096.
   PubMed Web of Science ®Google Scholar
• HAMURYUDAN V, OZYAZGAN Y, HIZLI N et al.: Azathioprine in Behget's syndrome: effects on long-term prognosis. Arthritic Rheum. (1997) 40:769–774.
   PubMed Web of Science ®Google Scholar
• MUDUN BA, ERGEN A, IPCIOGLU SU, BURUMCEK EY, DURLU Y,ARSLAN MO: Short-term chlorambucilafor refractory uveitis in Behget's disease. Immunol Inflamm. (2001) 9:219–229.
   PubMed Web of Science ®Google Scholar
• ERMAKOVA NA: Comparative evaluation of the effectiveness of corticosteroids and cytostatics in treating retinal angiitis in Behget's disease. Vestn. Ofralmol (2002) 118:32–35.
   PubMedGoogle Scholar
• SOLLO Y, OGE I, ERKAN D,ARITORK N, MOHAJERI F:Cyclosporine-A therapy in severe uveitis of Behget's disease. Acta. Ophthalmol Scand. (1998) 76:96–99.
   PubMedGoogle Scholar
• ATMACA LS, BATIOGLU F: The efficacy of cyclosporin A in the treatment of Behget's disease. Ophthalmic Surg. (1994) 25:321–327.
   PubMedGoogle Scholar
• FUJINO Y, JOKO S, MASUDA K et al: Cyclosporin microemulsion preconcentrate treatment of patients with Behget's disease. Jpn.j Ophthalmol (1999) 43:318–326.
   PubMedGoogle Scholar
• SIMSEK H, DONDAR S, TELATAR H: Treatment of Behget's disease with indomethacin. Int. .1. Dermatol (1991) 30:54–57.
   PubMed Web of Science ®Google Scholar
• O'DUFFY JD, ROBERTSON DM, GOLDSTEIN NP: Chlorambucil in the treatment of uveitis and meningoencephalitis of Behget's disease. Am. J. Med. (1984) 76:75–84.
   PubMed Web of Science ®Google Scholar
• HIROHATA S, SUDA H,HASHIMOTO T: Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behget's disease. J. NeuroL Sci. (1998) 159:181–185.
   PubMed Web of Science ®Google Scholar
• KOTAKE S, HIGASHI K,YOSHIKAWA K, SASAMOTO Y, OKAMOTO T, MATSUDA H: Central nervous system symptoms in patients with Behget's disease receiving cyclosporine therapy. Ophthalmology (1999) 106:586–589.
   PubMed Web of Science ®Google Scholar
• HAMURYUDAN V, YURDAKUL S, MORAL F et al.: Pulmonary artery aneurysms in Behget's syndrome: a report of 24 cases. Br: J. Rheumatol (1994) 33:48–51.
   Google Scholar
• TUNACI M, OZKORKMAZ B, TUNACI A, GOL A, ENGIN G, ACUNAS B: CT findings of pulmonary artery aneurysms during treatment for Behget's disease. Am. J. Roentgenol (1999) 172:729–733.
   PubMed Web of Science ®Google Scholar
• ORTEGA M, GARCIA A, MARTINEZ V, CALLEJA J: Usefulness of the blink reflex in a case of brainstem neuro-Behget's disease. Rev Neurol (2001) 32:67–70.
   PubMedGoogle Scholar
• ABADOGLU 0, OSMA E, UCAN ES et al.: Behget's disease with pulmonary involvement, superior vena cava syndrome, chyloptysis, and chylous ascites. Respir. Med. (1996) 90:429–431.
   Google Scholar
• ERKAN F, CAVDAR T: Pulmonary vasculitis in Behget's disease. Am. Rev Respir. Dis. (1992) 146:232–239.
   PubMedGoogle Scholar
• CHOI IJ, KIM JS, CHA SD et al.: Long-term clinical course and prognostic factors in intestinal Behget's disease. Dis. Colon Rectum (2000) 43:692–700.
   PubMed Web of Science ®Google Scholar
• TODA K, SHIRATORI Y, YASUDA M et al.: Therapeutic effect of intraarterialprednisolone injection in severe intestinalBehget's disease. J. Castroenterol (2002) 37:844–848.
   PubMedGoogle Scholar
• JORIZZO JL, SCHMALSTIEG FC, SOLOMON AR Jr et al.: Thalidomide effects in Behget's syndrome and pustular vasculitis. Arch. Intern. Med. (1986) 146:878–881.
   Google Scholar
• HAMZA MH: Treatment of Behget's disease with thalidomide. Clin. Rheumatol (1986) 5:365–371.
   PubMed Web of Science ®Google Scholar
• DE WAZIERES B, GIL H, MAGY N, BERTHIER S, VUITTON DA, DUPOND JL: Treatment of recurrent ulceration with low doses of thalidomide: pilot study in 17 patients. Rev Med. Interne. (1999) 20:567–570.
   PubMedGoogle Scholar
• GARDNER-MEDWIN JM, SMITH NJ, POWELL RJ: Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behget's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann. Rheum. Dis. (1994) 53:828–832.
   PubMed Web of Science ®Google Scholar
• •This prospective study demonstrated the effectiveness of thalidomide in BD patients recalcitrant to other therapies.
   Google Scholar
• HAMURYUDAN V, MAT C, SAIP S et al: Thalidomide in the treatment of the mucocutaneous lesions of the Behget's syndrome: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. (1998) 128:443–450.
   PubMed Web of Science ®Google Scholar
• •This 24-week clinical study showed the effectiveness of thalidomide in the mucocutaneous lesions of BD, though the complete response is insignificant.
   Google Scholar
• YAZICI H, YURDAKUL S, HAMURYUDAN V: Behget disease. Carr. Opin. Rheumatol (2001) 13:18–22.
   PubMed Web of Science ®Google Scholar
• TREVES R, ARNAUD M, JACOB P et al: Speculative amelioration of arthritis in Behget disease with thalidomide: a case report. Rev Rhum. Mal. Osteoartic. (1984) 51:585.
   PubMedGoogle Scholar
• RANSELAAR CG, BOONE RM, KLUIN-NELEMANS HC: Thalidomide in the treatment of neuro-Behget's syndrome. Br: J. Dermatol (1986) 115:367–370.
   PubMed Web of Science ®Google Scholar
• MUNRO CS, COX NH: Pyoderma gangrenosum associated with Behget's syndrome-response to thalidomide. Clin. Exp. Dermatol (1988) 13:408–410.
   PubMed Web of Science ®Google Scholar
• LARSSON H: Treatment of severe colitis in Behget's syndrome with thalidomide(CG-217). J. Intern. Med. (1990) 228:405–407.
   PubMed Web of Science ®Google Scholar
• HEGAB S, AL-MUTAWA S:Immunopathogenesis of Behget's disease. Clin. Immunol (2000) 96:174–186.
   PubMedGoogle Scholar
• KARI JA, SHAH V, DILLON MJ: Behget's disease in UK children: clinical features and treatment including thalidomide. Rheumatology (2001) 40:933–938.
   PubMed Web of Science ®Google Scholar
• MOCHIZUKI M, IKEDA E, SHIRAO M, FUJITO S, YOSHIMURA K,SHIMADA N: Preclinical and clinical study of FK506 in uveitis. Carr: Eye. Res. (1992) 11:87–95.
   Google Scholar
• MOCHIZUKI M: Immunotherapy for Behget's disease. Intern. Rev Immunol (1997) 14:49–66.
   PubMedGoogle Scholar
• SLOPER CM, POWELL RJ, DUA HS: Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology (1999) 106:723–728.
   PubMed Web of Science ®Google Scholar
• ••This study showed the effectiveness oftacrolirnus in patients with sight-threatening uveitis refractory to cyclosporine A.
   Google Scholar
• KOGA T, YANO T, ICHIKAWA Y, OIZUMI K, MOCHIZUKI M: Pulmonary infiltrates recovered by FK506 in a patient with Behget's disease. Chest (1993) 104:309–311.
   PubMed Web of Science ®Google Scholar
• DE TRAN QH, GUAY E, CHARTIER S, TOUSIGNANT J: Tacrolimus in dermatology. I Cutan. Med. Surg. (2001) 5:329–335.
   PubMedGoogle Scholar
• MOCHIZUKI M, MASUDA K, SAKANE T et al.: A clinical trial of FK506 in refractory uveitis. Am. Ophthalmol (1993) 115:763–769.
   PubMed Web of Science ®Google Scholar
• •This study demonstrated the effectiveness of tacrolirnus in 41 BD patients with refractory uveitis.
   Google Scholar
• HAMURYUDAN V, MORAL F, YURDAKUL S et al.: Systemic interferon a-26 treatment in Behget's syndrome. Rheumatol (1994) 21:1098–1100.
   Google Scholar
• •This study reported the beneficial effects of IFN-a2, in the treatment of arthritis in BD.
   Google Scholar
• NICHOLS JC, INCE A, AKDUMAN L, MANN ES: Interferon-a 2a treatment of neuro-Behget disease. Neuroophthalmol (2001) 21:109–111.
   PubMed Web of Science ®Google Scholar
• ALPSOY E, DURUSOY C, YILMAZ E et al.: Interferon alfa-2a in the treatment of Behget disease: a randomized placebo-controlled and double-blind study. Arch. Dermatol (2002) 138:467–471.
   PubMed Web of Science ®Google Scholar
• ••This study demonstrated an effective therapy for mucocutaneous and ocular symptoms by IFN-4: 1„.
   Google Scholar
• O'DUFFY JD, CALAMIA K, COHEN S et al.: Interferon-a treatment of Behget's disease. Rheumatol (1998) 25:1938–1944.
   Google Scholar
• •This study showed the effectiveness of IFN-a for the treatment of mucocutaneous and articular symptoms of BD patients, but in a limited number of cases.
   Google Scholar
• KOSAR A, HAZNEDAROGLU S, KARAASLAN Yet al.: Effects of interferon-a2a treatment on serum levels of tumor necrosis factor-a, tumor necrosis factor-a2 receptor, interleukin-2, interleukin-2 receptor, and E-selectin in Behget's disease. Rheumatol Int. (1999) 19:11–14.
   Google Scholar
• CALGONERI M, OZTORK MA, ERTENLI I, KIRAZ S, APRAS S, OZBALKAN Z: Effects of interferon-a treatment on the clinical course of refractory Behget's disease: an open study. Ann. Rheum. Dis. (2003) 62:492–493.
   PubMedGoogle Scholar
• ••This is an uncontrolled study suggestingan effective and safe therapy with IFN-a where sight or life is threatened.
   Google Scholar
• KOTTER I, ZIERHUT M,ECKSTEIN AK et al: Human recombinant interferon alfa-2a for the treatment of Behget's disease with sight threatening posterior or panuveitis. Br. I Ophthalmol (2003) 87:423–431.
   PubMed Web of Science ®Google Scholar
• ••This is an open, non-randomised,uncontrolled, prospective clinical trial showing to significant improvement of vision and complete remission of ocular vasculitis in the majority of the patients.
   Google Scholar
• SFIKAKIS PP, THEODOSSIADIS PG, KATSIARI CG, KAKLAMANIS P, MARKOMICHELAKIS NN: Effect of infliximab on sight-threatening panuveitis in Behget's disease. Lancet (2001) 358:295–296.
   PubMed Web of Science ®Google Scholar
• ROBERTSON LP, HICKLING P: Treatment of recalcitrant orogenital ulceration of Behget's syndrome with Infliximab. Rheumatology (2001) 40:473–474.
   PubMed Web of Science ®Google Scholar
• SFIKASIS PP: Behget's disease: a new target for anti-tumour necrosis factor treatment. Ann. Rheum. Dis. (2002) 61:51–53.
   Google Scholar
• MUNOZ-FERNANDEZ S, HIDALGO V, FERNANDEZ-MELON J, SCHLINCKER A, MARTIN-MOLA E: Effect of infliximab on threatening panuveitis in Behget's disease.Lancet (2001) 358:1644.
   Google Scholar
• LICATA G, PINTO A,TUTTOLOMONDO A et al: Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behget's syndrome. Ann. Rheum. Dis. (2003) 62:280–281.
   PubMedGoogle Scholar
• KRAM MT, MAY LD, GOODMAN S, MOLINAS S: Behget's ileocolitis: successful treatment with tumor necrosis factor-alphaantibody (infliximab) therapy: report of a case. Dis. Colon Rectum (2003) 46:118–121.
   PubMedGoogle Scholar
• TRAVIS SP, CZAJKOWSKI M, MCGOVERN DP, WATSON RG, BELL AL: Treatment of intestinal Behget's syndrome with chimeric tumor necrosis factor alpha antibody. Gut (2001) 49:725–728.
   PubMed Web of Science ®Google Scholar
• HASSARD PV, BINDER SW,NELSON V, VASILIAUSKAS EA: Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behget's disease: a case report. Gastroenterology (2001) 120:995–999.
   PubMed Web of Science ®Google Scholar
• MUSSACK T, LANDAUER N,LADURNER R et al.: Successful treatment of cervical esophageal perforation in Behget's disease with drainage operation and infliximab. Am. Gastroenterol (2003) 98:703–704.
   Google Scholar